December 7, 2021

Olympus Sets Sights on Growth in Its Refocused Medical BusinessCompany to Focus on Elevating the Standard of Care in Targeted Disease States⚫
⚫
⚫

Plans include sharper focus on gastrointestinal, urological and respiratory care
Investment in single-use endoscopes, digital solutions, and endoluminal therapies
expected
Expanded R&D capabilities, stronger medical and scientific affairs, and other enabling
factors will support better execution of Olympus’ medical business

TOKYO – December 7, 2021 – Olympus Corporation (“Olympus” – Director, Representative
Executive Officer, President and CEO: Yasuo Takeuchi), has clarified the direction of its
medical business with the aim of achieving further growth and profitability by elevating thestandard of care in targeted disease states. The medtech leader’s approach involves greater
focus on gastrointestinal, urological, and respiratory care solutions for chronic diseases thatwill increasingly impact the global population, as well as more focused investment in nextgeneration technologies that will enhance patient care pathways.
Three major principles guide the company’s approach:
1.

Focus the portfolio on disease states where Olympus can maximize impact
Olympus will focus on the disease states where it can maximize its positive impact,
including those targeted by its Gastrointestinal, Urology, and Respiratory businessareas. Aging populations worldwide face increasing levels of chronic disease that
present unmet needs matching Olympus’ competitive strengths, as well as
opportunities to continue providing solutions for colorectal cancer, benign prostatic
hyperplasia, urological stone disease, urinary disease, and lung cancer. Other medical
areas will remain important business components and support Olympus’ goal of
striving for greater profitability, contributing to the company-wide goal of at least 56% annual growth and an operating profit margin of 20% or higher.

2.

Shape the future by investing in new ways to enhance the standard of care
Olympus will concentrate on a care pathway-oriented approach, proceduraloptimization, and next-generation solutions development. The company’s innovation
pipeline includes plans to optimize its endoscope line through complementary
single-use scopes; integrate computer-assisted diagnosis, cloud, and endoscopy
workflow management technologies; and explore endoluminal therapy breakthroughs.

3.

Enable Olympus to compete even more effectively on a global scale
The company’s approach includes enabling factors, such as an expanded global R&D
network, stronger Medical and Scientific Affairs, and a more centralized Quality-1-

Assurance and Regulatory Affairs function. Merger and acquisition momentum isexpected to stay strong via the Olympus business development function, which drove
significant acquisitions over the past 2 years. Additionally, the new Olympus wholly
owned corporate venture capital fund will prioritize early-stage investments and aim
to stimulate next-generation innovations.
Olympus’ new direction comes on the back of strong half-year figures, including a record
operating profit margin of 18.5% and strong year-on-year growth of 31%, as announced on
November 5. Medical business revenue is expected to reach a record high for fiscal year 2022.
Olympus also reiterated its goal of operating with a 20%-plus profit margin and a midterm
annual growth rate of 5-6% in fiscal year 2023.
Since 2019, Olympus has completed the sale of its Imaging business and announced theimpending transition of its Scientific Solutions business into a newly established, wholly owned
subsidiary. A package of operational changes brought about enhancements in efficiency,profitability, R&D processes, and customer care.
“We are witnessing stunning changes to the global healthcare industry due to the aging ofpopulations, the rise of chronic diseases, integration of digital technologies, health and biotech
advancements and a growing emphasis on less-invasive treatments,” said Yasuo Takeuchi,President and CEO of Olympus. “With the successful transformation of Olympus since 2019, wehave become a global medtech leader. Today we have unveiled a unifying value creation
direction that is designed to elevate the standard of care, optimize the treatment journey forpatients and healthcare professionals, and benefit all stakeholders, while accelerating ourability to deliver on the profitability and growth targets we have set.”
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial
equipment industries. For more than 100 years, Olympus has focused on making people’s lives healthier,safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; andensuring public safety. As a leading medical technology company, our Medical business uses innovative
capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare
professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes,
reduce overall costs, and enhance the quality of life for patients. Olympus’ Medical portfolio includes
endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, customer
solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic
applications. For more information, visit www.olympus-global.com and follow our global Twitter account:@Olympus_Corp.

-2-